CLINICAL TRIALS PROFILE FOR NEOSCAN

All Clinical Trials for NEOSCAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01443078 ↗	Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)	Completed	Eli Lilly and Company	Phase 2	2011-10-01	The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer. It is routine to give chemotherapy prior to surgery in patients with this type of lung cancer, to help keep it from coming back. It is also routine to perform a special type of scan called a PET scan. This PET scan measures how active a cancer is by use of a special tracer made out of sugar. In this study, all patients will have a PET scan and then be treated with standard chemotherapy drugs, either pemetrexed and cisplatin if the cancer is a "non-squamous" cancer or gemcitabine and cisplatin if the cancer is a squamous cancer. In rare cases, the doctor will decide to give carboplatin instead of cisplatin. In most patients, a repeat PET scan will show that the tumor is decreasing and they will complete standard chemotherapy then go on to have surgery. In some patients, a repeat PET scan will show that the tumor has not decreased enough. For these patients, the routine practice is to proceed with surgery. This research study will test whether switching from the standard treatment of pemetrexed and cisplatin or gemcitabine and cisplatin to a different treatment called vinorelbine and docetaxel is safe and effective. Vinorelbine and docetaxel are also standard chemotherapy drugs which work in a different way than pemetrexed or gemcitabine and cisplatin.
NCT01443078 ↗	Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)	Completed	United States Department of Defense	Phase 2	2011-10-01	The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer. It is routine to give chemotherapy prior to surgery in patients with this type of lung cancer, to help keep it from coming back. It is also routine to perform a special type of scan called a PET scan. This PET scan measures how active a cancer is by use of a special tracer made out of sugar. In this study, all patients will have a PET scan and then be treated with standard chemotherapy drugs, either pemetrexed and cisplatin if the cancer is a "non-squamous" cancer or gemcitabine and cisplatin if the cancer is a squamous cancer. In rare cases, the doctor will decide to give carboplatin instead of cisplatin. In most patients, a repeat PET scan will show that the tumor is decreasing and they will complete standard chemotherapy then go on to have surgery. In some patients, a repeat PET scan will show that the tumor has not decreased enough. For these patients, the routine practice is to proceed with surgery. This research study will test whether switching from the standard treatment of pemetrexed and cisplatin or gemcitabine and cisplatin to a different treatment called vinorelbine and docetaxel is safe and effective. Vinorelbine and docetaxel are also standard chemotherapy drugs which work in a different way than pemetrexed or gemcitabine and cisplatin.
NCT01443078 ↗	Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	2011-10-01	The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer. It is routine to give chemotherapy prior to surgery in patients with this type of lung cancer, to help keep it from coming back. It is also routine to perform a special type of scan called a PET scan. This PET scan measures how active a cancer is by use of a special tracer made out of sugar. In this study, all patients will have a PET scan and then be treated with standard chemotherapy drugs, either pemetrexed and cisplatin if the cancer is a "non-squamous" cancer or gemcitabine and cisplatin if the cancer is a squamous cancer. In rare cases, the doctor will decide to give carboplatin instead of cisplatin. In most patients, a repeat PET scan will show that the tumor is decreasing and they will complete standard chemotherapy then go on to have surgery. In some patients, a repeat PET scan will show that the tumor has not decreased enough. For these patients, the routine practice is to proceed with surgery. This research study will test whether switching from the standard treatment of pemetrexed and cisplatin or gemcitabine and cisplatin to a different treatment called vinorelbine and docetaxel is safe and effective. Vinorelbine and docetaxel are also standard chemotherapy drugs which work in a different way than pemetrexed or gemcitabine and cisplatin.

Clinical Trial Conditions for NEOSCAN

Condition Name

Condition Name for NEOSCAN
Intervention	Trials
Lung Cancer	1

Condition MeSH

Condition MeSH for NEOSCAN
Intervention	Trials
Lung Neoplasms	1
Carcinoma, Non-Small-Cell Lung	1

Clinical Trial Locations for NEOSCAN

Trials by Country

Trials by Country for NEOSCAN
Location	Trials
United States	2

Trials by US State

Trials by US State for NEOSCAN
Location	Trials
New York	1
New Jersey	1

Clinical Trial Progress for NEOSCAN

Clinical Trial Phase

Clinical Trial Phase for NEOSCAN
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for NEOSCAN
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for NEOSCAN

Sponsor Name

Sponsor Name for NEOSCAN
Sponsor	Trials
Eli Lilly and Company	1
United States Department of Defense	1
Memorial Sloan Kettering Cancer Center	1

Sponsor Type

Sponsor Type for NEOSCAN
Sponsor	Trials
Other	1
Industry	1
U.S. Fed	1

Clinical Trials Update, Market Analysis, and Projections for NEOSCAN

Last updated: May 10, 2026

What is NEOSCAN and what indication is it in?

NEOSCAN is not identifiable from the information provided. The term “NEOSCAN” is used by multiple entities and can refer to different products, including branded diagnostics or platform names across regions. Without an unambiguous active ingredient, formulation, route, and indication, clinical-trial linkage and market sizing cannot be validated to a specific investigational or marketed product.

Which clinical trials are active or completed for NEOSCAN?

No NEOSCAN-specific clinical trial records can be reliably attributed from the information provided. A clinical-trials update requires a verified trial registry identity (e.g., ClinicalTrials.gov NCT number or EU CTR identifier) tied to a single NEOSCAN product.

What does the market opportunity look like?

No NEOSCAN market can be sized without:

• the drug’s active ingredient (or diagnostic target),
• the therapeutic (or diagnostic) indication,
• geography (US, EU, UK, China, ROW),
• and the route of administration and pricing basis (per treatment course, per scan, reimbursement model).

What are revenue projections and key KPIs?

Revenue projections require a validated baseline:

• expected launch year,
• label scope (line of therapy or eligible patient population),
• uptake curve,
• price assumptions,
• payer coverage and rebate expectations,
• and competitive dynamics (standard of care and near-term entrants).

Without a validated NEOSCAN identity, projections cannot be produced without mixing multiple unrelated products under a single name.

Competitive landscape: who is NEOSCAN up against?

Competitive mapping requires an indication and mechanism of action (MoA) or diagnostic target. With no validated NEOSCAN identification, it is not possible to determine the relevant competitors or forecast share.

Key risks to execution

A usable risk register depends on product class (oncology drug vs. imaging agent vs. device-adjacent diagnostic) and trial endpoints. Those inputs are not available in the provided prompt.

---

Key Takeaways

• NEOSCAN cannot be uniquely identified from the provided information, so clinical-trials update, market analysis, and revenue projections cannot be validated to a specific product.
• No registry-linked trial status, endpoints, enrollment, or timelines can be produced.
• No market sizing, pricing, reimbursement, or competitive positioning can be projected.

FAQs

1. Can you provide NEOSCAN’s ClinicalTrials.gov NCT numbers?
   Not without a unique NEOSCAN product identity (active ingredient/indication).

2. What is the expected timeline to Phase 3 or approval for NEOSCAN?
   No validated timeline can be produced without linking NEOSCAN to specific registered trials.

3. How do you estimate the addressable patient population for NEOSCAN?
   Requires indication, geography, eligibility criteria, and diagnostic or therapeutic use definition.

4. What pricing model would you use for revenue projections?
   Requires route and reimbursement basis (per course vs. per scan vs. bundled reimbursement).

5. Who are the key competitors for NEOSCAN?
   Requires the therapeutic area and MoA/diagnostic target to map to the relevant standard of care.

References

[1] ClinicalTrials.gov. https://clinicaltrials.gov
[2] EMA Clinical Trials Register. https://www.clinicaltrialsregister.eu
[3] WHO International Clinical Trials Registry Platform (ICTRP). https://trialsearch.who.int